Loading stock data…
TOVX
$0.33+0.01 (+2.52%)
Pre-Market$0.33+0.00 (+0.00%)· Last close May 13
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Theriva Biologics, Inc. in the Healthcare sector is trading at $0.33. Wall Street consensus targets $2.50 (2 analysts), implying a +657.6% move over the next 12 months. The stock is currently 62% below its 52-week high of $0.86, remaining 10.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +657.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$0.33
Potential Downside
0%
Whystock Fair Value$0.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-154.32%
Volume
Today's trading volume
1.49M
Recent News
Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design
Theriva Biologics (TOVX) announced the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use of the European Medicines Agency on the design of a Phase 3 clinical trial of lead clinical candidate VCN-01 in combination with gemcitabine/nab-paclitaxel standard-of-care chemotherapy for the first-line treatment of metastatic PDAC. The Company has previously reported the results of the VIRAGE randomized, controlled Phase 2b clinical trial, demonstrating that PDAC patient
Theriva Biologics: Q3 Earnings Snapshot
ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Wednesday reported a loss of $4.4 million in its third quarter.
Theriva Biologics: Q2 Earnings Snapshot
ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Monday reported a loss of $13.1 million in its second quarter.
Theriva Biologics: Q1 Earnings Snapshot
ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Wednesday reported a loss of $4.3 million in its first quarter.